Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Rhea-AI Summary

Neovasc Inc. (NASDAQ, TSX: NVCN) will announce its financial results for the quarter and full year ended December 31, 2021, on March 10, 2022. The conference call will feature CEO Fred Colen and CFO Chris Clark at 4:30 PM EDT. Interested participants can join by phone or webcast. Neovasc specializes in medical devices for cardiovascular treatment, including the Reducer for refractory angina and Tiara™ for mitral valve disease, both currently under clinical investigation in multiple regions.

VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on March 10, 2022.

Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13726770. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.

Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Mike.Cavanaugh@westwicke.com

Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@icrinc.com

FAQ

When will Neovasc report its financial results for 2021?

Neovasc will report its financial results for the quarter and full year ended December 31, 2021, on March 10, 2022.

Who will host the Neovasc conference call?

The conference call will be hosted by Neovasc's President and CEO Fred Colen and CFO Chris Clark.

How can I access the Neovasc conference call?

You can access the conference call by dialing (877) 407-9208 or (201) 493-6784 for international calls, referencing Conference ID 13726770.

What products does Neovasc develop?

Neovasc develops medical devices for cardiovascular treatment, including the Reducer for refractory angina and Tiara™ for mitral valve disease.